Kailera Therapeutics Inc
NAS:KLRAHealthcareCBOEFTSE:MRUTNASDAQ:NQUSSG$12.89+12.77%At closeAt close · Wed 21 Oct · ≈ AED 47.34 · Market cap $1.67B · Next earnings Wed 2 Dec
| USD millions | FY2024 | FY2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Cost of revenue | 0.1 | 0.0 |
| Gross profit | (0.1) | 0.0 |
| Research & development | 7.0 | 109.1 |
| Selling, general & administrative | — | 49.2 |
| Selling & marketing | — | 0.0 |
| Operating expenses | 16.3 | 158.3 |
| Operating income | (16.3) | (158.3) |
| Interest expense | 0.0 | 0.0 |
| Interest income | 2.5 | 11.0 |
| Other income / expense | — | 9.4 |
| Pre-tax income | (219.7) | (149.0) |
| Income tax | 0.0 | 0.0 |
| Net income | (219.7) | (149.0) |
| Discontinued operations | — | 0.0 |
| Other net income adjustments | — | 0.0 |
| EPS, basic (per share) | (2.60) | (1.26) |
| EPS, diluted (per share) | (2.60) | (1.26) |
| EBITDA | (16.3) | (158.0) |
| Depreciation & amortization | 0.1 | 0.3 |
| Weighted average shares (shares) | 84,615,439 | 117,948,773 |
| Weighted average diluted shares (shares) | 84,615,439 | 117,948,773 |
USD millionsUpdated Wed 12 Aug ·
ⓘ
Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.
